Intrafusin (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

Intrafusin delivers a balanced blend of essential amino acids directly into the bloodstream, bypassing the digestive system. These amino acids serve as building blocks for protein synthesis, support metabolic pathways such as gluconeogenesis, and contribute to neurotransmitter production, thereby sustaining cellular function and immune competence when oral intake is insufficient.

The dose of Intrafusin is individualized and set by the prescribing clinician based on the patient’s weight, clinical condition, and nutritional requirements. Healthcare professionals calculate the appropriate amount to achieve the desired amino acid intake while monitoring laboratory parameters and patient response.

Safety data for Intrafusin in pregnancy and lactation are limited. Because it is an amino acid formulation, it may be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate each case carefully and consider alternative nutrition strategies when possible.

To order Intrafusin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Intrafusin offers a comprehensive profile of essential amino acids in a single intravenous formulation, designed to meet the full spectrum of protein synthesis needs. Compared with some single‑amino‑acid or limited‑profile solutions, Intrafusin provides a more balanced amino acid composition, potentially reducing the need for multiple additives and simplifying nutrition regimens.

Intrafusin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, inspect the container for any signs of contamination or particulate matter, and allow the solution to reach room temperature if required by the administration protocol.

Intrafusin is administered intravenously, typically via a peripheral or central venous catheter. The infusion rate and total volume are determined by the prescribing clinician and should follow institutional protocols for parenteral nutrition, ensuring aseptic technique and appropriate monitoring during and after the infusion.

The most serious risks include severe allergic reactions such as anaphylaxis, hyperammonemia in susceptible patients, and metabolic acidosis. Prompt recognition of these events is essential; immediate medical intervention, including discontinuation of the infusion and supportive care, may be required.

Intrafusin is contraindicated in individuals with known hypersensitivity to any of its amino acid components. Caution is advised for patients with severe renal or hepatic impairment, uncontrolled metabolic disorders, or those receiving medications that significantly increase ammonia production, as they may be at higher risk for adverse reactions.